Breaking news & independent expert insights across pharma, biotech & medtech. Built for the life sciences community. Visit lifesciencedaily.news
Joined June 2025
- Tweets 111
- Following 58
- Followers 12
- Likes 0
10 Photos and videos
One study. Three EU regulators. Three incompatible answers on the same companion diagnostic.
Why IVDR fragmentation keeps stalling Europe's precision oncology trials, and what sponsors can do now. lifesciencedaily.news/eu-ivd… #IVDR #PrecisionOncology
6
Sanofi has halted its Phase 3 riliprubart trial in CIDP after monitors judged it unlikely to hit efficacy goals. No safety flags. What it means for argenx and Dianthus: lifesciencedaily.news/comple… #Biopharma #ClinicalTrials
46
4 Phase 3 readouts this week: 63% liver fat reduction with survodutide, twice the remission rate in PMR, a lupus endpoint cleared, and a bioengineered vessel beating standard dialysis access. Our 12 June Clinical Trials Roundup: lifesciencedaily.news/clinic… #ClinicalTrials
22
Updated Post: Foundayo vs Rybelsus: The Oral GLP-1 Guide for 2026 lifesciencedaily.news/founda…
ALT Two oral GLP-1 prescription pill bottles labelled Foundayo and Rybelsus positioned side by side with white tablets, illustrating the comparison between the two oral GLP-1 medications.
38
Fixed Phase 3 protocols lock in assumptions before a single patient is enrolled. When those assumptions are wrong, everyone loses. Lew Bender makes the case for adaptive trial design lifesciencedaily.news/adapti… #ClinicalTrials #AdaptiveTrialDesign #Biopharma
4
GSK is paying $10.6bn for Nuvalent and two FDA decision dates now decide if the premium was worth it. Two brain-penetrant NSCLC drugs. Two PDUFA dates before year end. Full analysis: lifesciencedaily.news/gsk-nu… #GSK #Nuvalent #Oncology #NSCLC
23
The FDA's busiest approval window of 2026 is here. Datroway approved. Ensitrelvir approved. Gedatolisib and atacicept decisions due in July. All of this with a new acting commissioner in post. Full breakdown at lifesciencedaily.news/fda-dr… #FDA #Biopharma #DrugApproval
46
New Post: Importance of Targeted Radiotherapeutics in Treating CNS Cancers lifesciencedaily.news/target…
5
Empathy fatigues. Compassion does not. New research shows the difference is neurological, and it may be key to tackling healthcare burnout. Read more: lifesciencedaily.news/how-co… #Burnout #Healthcare
2
A 60% reduction in risk of death in second-line pancreatic cancer. Revolution Medicines' daraxonrasib vs chemotherapy: 13.2 vs 6.6 months median OS. The RASolute 302 Phase 3 data presented at #ASCO2026 are now published in NEJM. Full breakdown lifesciencedaily.news/daraxo…
44
Updated Post: Clinical Insight: The Future of Sensory-Based Therapeutics in Healthcare lifesciencedaily.news/sensor…
ALT Diagram of sensory-based therapeutics pathways showing olfactory, auditory, and tactile routes to the brain
3
Up to 67% of Australian healthcare workers reported verbal abuse in a single year. A new article examines why workplace bullying in healthcare persists and what leadership must do differently. lifesciencedaily.news/workpl… #WorkplaceBullying #PatientSafety
2
New Post: Weekly News Roundup | 8 June 2026 lifesciencedaily.news/life-s…
5
New Post: The Scaling Crisis in Cell and Gene Therapy lifesciencedaily.news/cell-a…
7
New Post: 86 FDA-approved biosimilars. $56bn in US healthcare savings. And Keytruda biosimilars are now in sight. What's been cleared in 2026 and what comes next: lifesciencedaily.news/biosim… #Biosimilars #Biopharma #FDA
1
27
One infusion. Up to 88% PCSK9 reduction. Up to 62% LDL cut. Effects lasting 18 months. VERVE-102 base editing data published in NEJM, plus three more significant trial results: lifesciencedaily.news/clinic… #ClinicalTrials #GeneEditing
12
60% reduction in risk of death in pancreatic cancer. 5,000 NHS patients a year potentially spared from chemo. ASCO 2026 delivered five practice-changing results. Full breakdown: lifesciencedaily.news/asco-2… #ASCO2026 #Oncology
25
Retatrutide hit 28.3% mean weight loss in Phase 3. Two new GLP-1s already approved in 2026. CagriSema still pending. We mapped the full pipeline. lifesciencedaily.news/glp-1-… #GLP1 #Pharma #DrugPipeline
58
New Post: Why AI Alone Cannot Solve Healthcare’s Data Fragmentation Problem lifesciencedaily.news/why-ai…
4
Replication rates in biomedical AI are reportedly below 50%. Yet performance claims keep multiplying. Without shared benchmarking standards, how does drug discovery separate real progress from noise? lifesciencedaily.news/withou… #AIDrugDiscovery #Benchmarking #DrugDiscovery
8